NASDAQ: CADL
Candel Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for CADL

Based on 3 analysts offering 12 month price targets for Candel Therapeutics Inc

Min Forecast
$18.00+63.34%
Avg Forecast
$21.00+90.56%
Max Forecast
$23.00+108.71%

Should I buy or sell CADL stock?

Based on 3 analysts offering ratings for Candel Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CADL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CADL as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their CADL stock forecasts and price targets.

CADL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-21
lockedlocked$00.00+00.00%2026-08-13
lockedlocked$00.00+00.00%2026-07-13
lockedlocked$00.00+00.00%2026-04-20

1 of 1

Forecast return on equity

Is CADL forecast to generate an efficient return?

Company
N/A
Industry
22.19%
Market
168.26%

Forecast return on assets

Is CADL forecast to generate an efficient return on assets?

Company
N/A
Industry
23.8%

CADL earnings per share forecast

What is CADL's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$1.49
Avg 2 year Forecast
-$1.15
Avg 3 year Forecast
$0.09

CADL revenue forecast

What is CADL's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$44.3M
Avg 3 year Forecast
$208.5M

CADL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CADL$11.02$21.00+90.56%Strong Buy
ARDX$3.42$12.50+265.50%Strong Buy
AVTX$15.47$45.73+195.59%Strong Buy
GYRE$7.35N/AN/A
ATTO$17.78$41.50+133.41%Strong Buy

Candel Therapeutics Stock Forecast FAQ

Is Candel Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: CADL) stock is to Strong Buy CADL stock.

Out of 3 analysts, 2 (66.67%) are recommending CADL as a Strong Buy, 1 (33.33%) are recommending CADL as a Buy, 0 (0%) are recommending CADL as a Hold, 0 (0%) are recommending CADL as a Sell, and 0 (0%) are recommending CADL as a Strong Sell.

If you're new to stock investing, here's how to buy Candel Therapeutics stock.

What is CADL's earnings growth forecast for 2026-2028?

(NASDAQ: CADL) Candel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.

Candel Therapeutics's earnings in 2026 is -$88,531,000.On average, 11 Wall Street analysts forecast CADL's earnings for 2026 to be -$114,249,869, with the lowest CADL earnings forecast at -$142,477,568, and the highest CADL earnings forecast at -$106,858,176. On average, 10 Wall Street analysts forecast CADL's earnings for 2027 to be -$88,065,216, with the lowest CADL earnings forecast at -$162,724,380, and the highest CADL earnings forecast at -$15,265,454.

In 2028, CADL is forecast to generate $6,909,626 in earnings, with the lowest earnings forecast at -$121,480,874 and the highest earnings forecast at $179,971,665.

What is CADL's revenue growth forecast for 2026-2028?

(NASDAQ: CADL) Candel Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.

Candel Therapeutics's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast CADL's revenue for 2026 to be $0, with the lowest CADL revenue forecast at $0, and the highest CADL revenue forecast at $0. On average, 11 Wall Street analysts forecast CADL's revenue for 2027 to be $3,386,099,538, with the lowest CADL revenue forecast at $0, and the highest CADL revenue forecast at $10,348,370,731.

In 2028, CADL is forecast to generate $15,950,294,874 in revenue, with the lowest revenue forecast at $4,799,244,397 and the highest revenue forecast at $29,382,363,774.

What is CADL's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CADL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 23.8%.

What is CADL's Price Target?

According to 3 Wall Street analysts that have issued a 1 year CADL price target, the average CADL price target is $21.00, with the highest CADL stock price forecast at $23.00 and the lowest CADL stock price forecast at $18.00.

On average, Wall Street analysts predict that Candel Therapeutics's share price could reach $21.00 by Sep 21, 2027. The average Candel Therapeutics stock price prediction forecasts a potential upside of 90.56% from the current CADL share price of $11.02.

What is CADL's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CADL) Candel Therapeutics's current Earnings Per Share (EPS) is -$1.42. On average, analysts forecast that CADL's EPS will be -$1.49 for 2026, with the lowest EPS forecast at -$1.86, and the highest EPS forecast at -$1.40. On average, analysts forecast that CADL's EPS will be -$1.15 for 2027, with the lowest EPS forecast at -$2.13, and the highest EPS forecast at -$0.20. In 2028, CADL's EPS is forecast to hit $0.09 (min: -$1.59, max: $2.35).

What is CADL's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CADL) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.